Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

RSV

- PMLiVE

Study shows infants given RSV vaccination benefit beyond first RSV season

The RSV virus is highly contagious and can cause serious respiratory illness for infants

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

The deal includes an early-stage combination vaccine candidate for RSV and hMPV

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

The vaccine is already approved in the US for use in adults aged 60 years and older

- PMLiVE

Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants

Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight

- PMLiVE

Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years

Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults

RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

- PMLiVE

UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance

The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year

- PMLiVE

GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons

The respiratory virus is estimated to impact 64 million people globally every year

- PMLiVE

GSK’s RSV vaccine Arexvy approved by EC for use in adults aged 50 to 59 years

An estimated 20 million adults in this age population are at an increased risk of severe RSV outcomes

- PMLiVE

Pfizer shares promising phase 3 results for RSV vaccine in immunocompromised adults

There are currently no RSV vaccines approved for adults aged 18 to 59 years in the US

- PMLiVE

UK government announces national RSV vaccination programme for infants and older adults

The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links